9441 related articles for article (PubMed ID: 17160167)
21. S-100beta and MIA in advanced melanoma in relation to prognostic factors.
Auge JM; Molina R; Filella X; Bosch E; Gonzalez Cao M; Puig S; Malvehy J; Castel T; Ballesta AM
Anticancer Res; 2005; 25(3A):1779-82. PubMed ID: 16033099
[TBL] [Abstract][Full Text] [Related]
22. [Serum S100B protein and stage of cutaneous melanoma: a prospective study].
Brouard M; Quillien V; Ollivier I; Lesimple T; Adamski H; Chevrant-Breton J
Ann Dermatol Venereol; 2000 Jan; 127(1):56-9. PubMed ID: 10717564
[TBL] [Abstract][Full Text] [Related]
23. The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection.
Kruijff S; Bastiaannet E; Speijers MJ; Kobold AC; Brouwers AH; Hoekstra HJ
Eur J Surg Oncol; 2011 Mar; 37(3):225-32. PubMed ID: 21277729
[TBL] [Abstract][Full Text] [Related]
24. MIA, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R
Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221
[TBL] [Abstract][Full Text] [Related]
25. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
[TBL] [Abstract][Full Text] [Related]
26. Serum ceruloplasmin in melanoma patients.
Ros-Bullón MR; Sánchez-Pedreño P; Martínez-Liarte JH
Anticancer Res; 2001; 21(1B):629-32. PubMed ID: 11299817
[TBL] [Abstract][Full Text] [Related]
27. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S
Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.
Wimmer I; Meyer JC; Seifert B; Dummer R; Flace A; Burg G
Cancer Res; 1997 Nov; 57(22):5073-6. PubMed ID: 9371505
[TBL] [Abstract][Full Text] [Related]
29. Value of tumour marker S-100B in melanoma patients: a comparison to 18F-FDG PET and clinical data.
Reinhardt MJ; Kensy J; Frohmann JP; Willkomm P; Reinhold U; Grünwald F; Biersack HJ; Bender H
Nuklearmedizin; 2002 Jun; 41(3):143-7. PubMed ID: 12109034
[TBL] [Abstract][Full Text] [Related]
30. Significance of serum S-100B in melanoma patients before and after sentinel node biopsy.
Smit LH; Nieweg OE; Korse CM; Bonfrer JM; Kroon BB
J Surg Oncol; 2005 May; 90(2):66-9; discussion 69-70. PubMed ID: 15844182
[TBL] [Abstract][Full Text] [Related]
31. Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein.
Beyeler M; Waldispuhl S; Strobel K; Joller-Jemelka HI; Burg G; Dummer R
Dermatology; 2006; 213(3):187-91. PubMed ID: 17033166
[TBL] [Abstract][Full Text] [Related]
32. Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH.
Egberts F; Pollex A; Egberts JH; Kaehler KC; Weichenthal M; Hauschild A
Onkologie; 2008 Jul; 31(7):380-4. PubMed ID: 18596385
[TBL] [Abstract][Full Text] [Related]
33. The current status of S-100B as a biomarker in melanoma.
Kruijff S; Hoekstra HJ
Eur J Surg Oncol; 2012 Apr; 38(4):281-5. PubMed ID: 22240030
[TBL] [Abstract][Full Text] [Related]
34. The value of serum S-100beta and interleukins as tumour markers in advanced melanoma.
Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Parvinen LM; Hahka-Kemppinen M; Korpela M; Kumpulainen E
Melanoma Res; 2000 Jun; 10(3):237-41. PubMed ID: 10890377
[TBL] [Abstract][Full Text] [Related]
35. Serum levels of melanoma-inhibiting activity do not predict relapse in melanoma patients.
Klimek VM; Williams L; Chapman PB
Cytokines Cell Mol Ther; 2002 Dec; 7(2):71-4. PubMed ID: 12607797
[TBL] [Abstract][Full Text] [Related]
36. Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma.
Bánfalvi T; Gilde K; Gergye M; Boldizsár M; Kremmer T; Ottó S
Eur J Cancer; 2003 Jan; 39(2):164-9. PubMed ID: 12509947
[TBL] [Abstract][Full Text] [Related]
37. Serum S-100B concentration provides additional information fot the indication of computed tomography in patients after minor head injury: a prospective multicenter study.
Biberthaler P; Linsenmeier U; Pfeifer KJ; Kroetz M; Mussack T; Kanz KG; Hoecherl EF; Jonas F; Marzi I; Leucht P; Jochum M; Mutschler W
Shock; 2006 May; 25(5):446-53. PubMed ID: 16680008
[TBL] [Abstract][Full Text] [Related]
38. Hemofiltration does not influence early S-100B serum levels in septic shock patients receiving stress doses of hydrocortisone or placebo.
Mussack T; Briegel J; Schelling G; Jochum M
Eur J Med Res; 2005 Feb; 10(2):81-7. PubMed ID: 15817428
[TBL] [Abstract][Full Text] [Related]
39. Serum S-100B is superior to neuron-specific enolase as an early prognostic biomarker for neurological outcome following cardiopulmonary resuscitation.
Shinozaki K; Oda S; Sadahiro T; Nakamura M; Abe R; Nakada TA; Nomura F; Nakanishi K; Kitamura N; Hirasawa H
Resuscitation; 2009 Aug; 80(8):870-5. PubMed ID: 19535196
[TBL] [Abstract][Full Text] [Related]
40. Heterogenous S-100B protein expression patterns in malignant melanoma and association with serum protein levels.
Bánfalvi T; Udvarhelyi N; Orosz Z; Gergye M; Gilde K; Tímár J
Oncology; 2003; 64(4):374-9. PubMed ID: 12759535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
